XORTX Therapeutics (XRTX) Enterprise Value (2020 - 2026)
XORTX Therapeutics' (XRTX) quarterly Enterprise Value came in at -$250275.0 in Q1 2026, up 86.79% YoY from -$133984.1 in Q1 2025, and up 71.05% on a QoQ basis from -$864514.0 in Q4 2025.
XORTX Therapeutics (XRTX) Enterprise Value (2020 - 2026) Analysis & Trends
XORTX Therapeutics (XRTX) has 7 years of Enterprise Value data on file, last reported at -$250275.0 in Q1 2026.
- Quarterly Enterprise Value rose 86.79% year-over-year to -$250275.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$250275.0 (up 86.79% YoY) and the FY2025 annual result came in at -$864514.0, up 65.05% from the prior year.
- Enterprise Value climbed to -$250275.0 in Q1 2026, from -$864514.0 in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$250275.0 in Q1 2026 to a low of -$12.2 million in Q1 2022.
- A 5-year average of -$4.6 million and a median of -$2.8 million in 2024 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2022 — Enterprise Value plunged 134.84% — and 2026, when it soared 86.79%.
- Tracing XRTX's Enterprise Value over 5 years: stood at -$10.4 million in 2022, then surged by 51.29% to -$5.1 million in 2023, then surged by 51.2% to -$2.5 million in 2024, then jumped by 65.05% to -$864514.0 in 2025, then surged by 71.05% to -$250275.0 in 2026.
- The last three Enterprise Value figures came in at -$250275.0 (Q1 2026), -$864514.0 (Q4 2025), and -$1.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.41 Bn | 130.56 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.12 Bn | 78.12 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.41 Bn | 59.23 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 57.56 Bn | 52.43 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.06 Bn | 36.96 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.95 Bn | 27.65 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 27.48 Bn | 9.09 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.31 Bn | 26.15 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.04 Bn | 26.20 Bn | - | 2.12 Bn |
| 10 | XORTX Therapeutics | 2.83 Mn | 2.83 Mn | - | -250,275.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -250,275.00 |
| Dec 31, 2025 | -864,514.00 |
| Sep 30, 2025 | -1.19 Mn |
| Jun 30, 2025 | -1.06 Mn |
| Mar 31, 2025 | -1.90 Mn |
| Dec 31, 2024 | -2.47 Mn |
| Sep 30, 2024 | -2.30 Mn |
| Jun 30, 2024 | -3.08 Mn |
| Mar 31, 2024 | -3.84 Mn |
| Sep 30, 2023 | -5.07 Mn |
| Dec 31, 2022 | -10.41 Mn |
| Sep 30, 2022 | -9.32 Mn |
| Jun 30, 2022 | -10.53 Mn |
| Mar 31, 2022 | -12.24 Mn |
| Dec 31, 2021 | -14.96 Mn |
| Sep 30, 2021 | -3.97 Mn |
| Dec 31, 2020 | -131,374.22 |